Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL343 Bioavailability and Food Effect in Healthy Participants
NCT04581772Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DNL343 in amyotrophic lateral sclerosis (ALS) and leukoencephalopathy with vanishing white matter (VWM) (3 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Maximum observed concentration up to 15 days, Time to maximum observed concentration up to 15 days and 2 more. Started Dec 2020; status: completed.
02
Drugs
DNL343
03
Conditions
amyotrophic lateral sclerosis (ALS)leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on NCT04581772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581772.